Our solid first-quarter performance is in line with our expectations for the quarter and demonstrates progress towards achieving our financial goals for the year. We continue to remain focused on preparing for potential new product launches in 2003.

Our performance continues to be driven by robust sales of our innovative oncology products which have helped nearly double our revenues in a three-year time period.

We're all pleased to see that there is some progress after all the expectations and anticipations.

Certainly the progress with the patient has been extremely pleasing, and I think it really surpasses any expectations that I've ever had,

Our earnings performance in the fourth quarter met expectations with increased gross margins, lower costs and operational improvements. We delivered another quarter - and another year - of earnings growth.

Although the underlying operating performance in the third quarter met our overall expectations, our fundamentals still need to be much stronger. As we discussed last week with the investment community, we expect to make meaningful progress going forward by simplifying our portfolio, aggressively attacking costs, and increasing investments behind key brands.